Inmunotek S.L.
Quick facts
Phase 3 pipeline
- Bactek-R · Immunology / Respiratory
Bactek-R is a bacterial lysate immunotherapy that stimulates innate and adaptive immune responses to enhance respiratory tract defenses. - Biological vaccine · Immunology
A biological vaccine that stimulates the immune system to recognize and attack disease-causing pathogens or abnormal cells. - MV140 · Immunology / Infectious Disease
MV140 is a polyvalent bacterial lysate vaccine that stimulates innate and adaptive immune responses to prevent recurrent urinary tract infections.
Phase 2 pipeline
- Clustoid® Max Forte · Immunology
Clustoid® Max Forte is an immunotherapeutic agent designed to modulate immune responses, likely through allergen immunotherapy or immune tolerance induction. - MG56 Mannosylated 1000 subcutaneous
- MG56 Mannosylated 1000 sublingual · Immunology
MG56 Mannosylated 1000 sublingual is designed to enhance immune response through targeted delivery to immune cells. - MG56 Mannosylated 3000 subcutaneous
- MG56 Mannosylated 3000 sublingual
- MG56 Mannosylated 500 subcutaneous
- MG56 Mannosylated 500 sublingual
- MG56 Mannosylated 5000 subcutaneous
- MG56 Mannosylated 5000 sublingual
- MM09 Mannosylated 10.000 subcutaneous
- MM09 Mannosylated 10.000 sublingual
- MM09 Mannosylated 30.000 subcutaneous
- MM09 Mannosylated 30.000 sublingual
- MM09 Mannosylated 5.000 subcutaneous
- MM09 Mannosylated 5.000 sublingual
- MM09 Mannosylated 50.000 subcutaneous
- MM09 Mannosylated 50.000 sublingual
- MV130
- VENOX
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: